Vinflunine: Antimitotic vinca alkaloid

Drugs of the Future

Volumn 29, Issue 6, 2004, Pages 574-580

  McIntyre, J A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; L 0070; MITOMYCIN C; NAVELBINE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINCA ALKALOID; VINFLUNINE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLADDER CANCER; BLADDER CARCINOMA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRAFT; CANCER INHIBITION; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; FATIGUE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; LUNG NON SMALL CELL CANCER; MICROTUBULE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; SEPSIS; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TUMOR;

EID: 3943060241     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.06.816574     Document Type: Article

References (43)

1. Jacquesy, J.-C., Fahy, J., Berrier, C., Bigg, D., Jouannetaud, M.-P., Zunino, F., Kruczynski, A., Kiss, R. (Pierre Fabre Médicament). Novel antimitotic binary alkaloid derivs. extracted from Catharanthus roseus. EP 0710240, FR 2707988, US 5620985, WO 9503312.
2. Fahy, J., Duflos, A., Ribert, J.-P., Jacquesy, J.-C., Berrier, C., Jouannetaud, M.-P., Zunino, F. Vinca alkaloids in superacidic media: A method for creating a new family of antitumor derivatives. J Am Chem Soc 1997, 119: 8576-7.
3. Jacquesy, J.-C., Berrier, C., Jouannetaud, M.-P., Zunino, F., Fahy, J., Duflos, A., Ribet, J.-P. Fluorination in superacids: A novel access to biologically active compounds. J Fluorine Chem 2002, 114: 139-41.
4. Duflos, A., Fahy, J., Thillaye du Boulay, V., Barret, J.-M., Hill, B. (Pierre Fabre Médicament). Vinca alkaloid antimitotic halogenated derivs. EP 0975640, JP 2001518892, US 6127377, WO 9845301.
5. Kruczynski, A., Barret, J.-M., Etiévant, C., Colpaert, F., Fahy, J., Hill, B.T. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 1998, 55: 635-48.
6. Lobert, S., Ingram, J.W., Hill, B.T., Correia, JJ. A comparison of thermodynamic parameters for vinorelbine- and vinf/unine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998, 53: 908-15.
7. Jean-Decoster, C., Brichese, L., Barret, J.-M., Tollon, Y., Kruczynski, A., Hill, B.T., Wright, M. Vinflunine, a new vinca alkaloid: Cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anti-Cancer Drugs 1999, 10: 537-43.
8. Kruczynski, A., Hill, B.T. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001, 40: 159-73.
9. Ngan, V.K., Bellman, K., Panda, D., Hill, B.T., Jordan, M.A., Wilson, L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 2000, 60: 5045-51.
10. Ngan, V.K., Bellman, K., Hill, B.T., Wilson, L., Jordan, M.A. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative Vinflunine. Mol Pharmacol 2001, 60: 225-32.
11. Okouneva, T., Hill, B.T., Wilson, L., Jordan, M.A. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003, 2: 427-36.
12. Kruczynski, A., Etiévant, C., Perrin, D., Chansard, N., Duflos, A., Hill, B.T. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer 2002, 86: 143-50.
13. Pourroy, B., Pasquier, E., Carré, M., Carles, G., André, N., Briand, C., Braguer, D. Apoptosis induced by Vinca alkaloids depends on mitochondria but not on mitotic block. Proc Am Assoc Cancer Res 2003, 44(2nd ed): Abst LB-13.
14. Kruczynski, A., Colpaert, F., Tarayre, J.-P., Mouillard, P., Fahy, J., Hill, B.T. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 1998, 41: 437-47.
15. Hill, B.T., Fiebig, H.-H., Waud, W.R., Poupon, M.-F., Colpaert, F., Kruczynski, A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 1999, 35: 512-20.
16. Fiebig, H.H., Hill, B.T., Burger, A.M., Gyselinck, N., Vincenti, M. Anticancer activity of vinflunide, a novel fluorinated vinca alkaloid in human gastric and melanoma models. Proc Am Assoc Cancer Res 2001, 42: Abst 1999.
17. Fiebig, H.-H., Hill, B.T., Burger, A.M., Gyselinck, N., Vincenti, M. Anticancer activity of vinflunine, a novel fluorinated vinca alkaloid in human pancreas, renal and non-small cell (NSCL) lung tumor xenografts. Proc Am Assoc Cancer Res 2002, 43: Abst 1331.
18. Kruczynski, A., Ricome, C., Astruc, J., Chazottes, E., Dejean, C., Berrichon, G., Hill, B. Significant antiangiogenic activity and marked inhibition of growth of an orthotopic colon cancer model and colon cancer liver métastases by vinflunine, the most recent vinca alkaloid in clinical development. Proc Am Assoc Cancer Res 2002, 43: Abst 1332.
19. Genne, P., Bichat, F., Duchamp, O., France, D., Auvray, P., Hill, B., Vincenti, M., Gyselinck, N. Antitumor activity study of vinflunide against a human small cell lung tumor xenografted in nude rats. Proc Am Assoc Cancer Res 2001, 42: Abst 1982.
20. Bonfil, R.D., Russo, D.M., Binda, M.M., Delgado, F.M., Vincenti, M. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic marine model of transitional cell carcinoma of the bladder. Urol Oncol 2002, 7: 159-66.
21. Kruczynski, A., Astruc, J., Chazottes, E., Berrichon, G., Ricome, C., Dejean, C., Duflos, A., Fahy, J., Hill, BT. Vinflunine, the latest Vinca alkaloid in clinical development, exhibits superior antiangiogenic activity relative to vinorelbine and Its derivatives. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst B22.
22. Etievant, C., Barret, J.-M., Kruczynski, A., Perrin, D., Hill, B.T. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998, 16: 3-17.
23. Etiévant, C., Kruczynski, A., Barret, J.-M., Tait, A.S., Kavallaris, M., Hill, B.T. Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′,4′- dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol 2001, 48: 62-70.
24. Barret, J.-M., Etiévant, C., Hill, B.T. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 2000, 45: 471-6.
25. Etievant, C., Barret, J.M., Cabrol, N., Offrete, V., Hill, B.T. Synergistic effects of the farnesyltransferase inhibitor SCH 66336 and novel Vinca alkaloids in A549 non-small cell lung cancer cells in vitro. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst 269.
26. Shnyder, S.D., Cooper, P.A., Gyselinck, N., Hill, B.T., Double, J.A., Bibby, M.C. Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model. Anticancer Res 2003, 23: 4815-20.
27. Holwell, S.E., Hill, B.T., Bibby, M.C. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 2001, 84: 290-5.
28. Hill, B.T, Barret, J.-M., Fahy, J., Kruczynski, A. In vitro and in vivo synergistic and additive effects of vinflunine, a novel fluorinated Vinca alkaloid currently in phase II trials in combination with other anticancer drugs. Proc Am Soc Clin Oncol 2001, 20(Part 2): Abst 2138.
29. Kruczynski, A., Ricome, C., Astruc, J., Chazottes, E., Dejean, C., Hill, B.T. Markedly augmented in vivo experimental antitumor activity with vinflunine, the most recent Vinca alkaloid to show activity in phase I clinical trials, when combined with DNA damaging anticancer agents. Proc Am Assoc Cancer Res 2002, 43: Abst 1333.
30. 3H-vinflunine in human blood: Binding to platelets and serum proteins. Proc Am Assoc Cancer Res 2002, 43: Abst 1047.
31. Bennouna, J., Fumoleau, P., Armand, J.-P, Raymond, E., Campone, M., Delgado, F.M., Puozzo, C., Marty, M. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 2003, 14: 630-7.
32. Armand, J-P., Fumoleau, P., Marty, M., Variol, P., Pinel, M.-C., Picard, M., Puozzo, C. Pharmacokinetics of vinflunine, a novel vinca alkaloid, during the phase I dose escalation study (D1 Q 3 weeks). Proc Am Assoc Cancer Res 2001, 42: Abst 2050.
33. Johnson, P., Judson, I., Ottensmeier, C., O'Donnell, A., Pinel, M.-C., Puozzo, C., Fumoleau, P. A phase I andpharmacokinetic study of vinflunine given on days 1 and 8 every 3 weeks. Br J Cancer 2001, 85(Suppl. 1): Abst P241.
34. Zorza, G., Johnson, P., Judson, I., Fumoleau, P., Diamand, F. A phase I pharmacokinetic study of vinflunine given on days 1 and 8 every 3 weeks. Proc Am Soc Clin Oncol 2001, 20(Part 2): Abst 2070.
35. Puozzo, C., Vermorken, J.B., Bauer, J., Bugat, R., Pinel, M.-C. A phase I pharmacokinetic study of vinflunine given on a weekly schedule. Proc Am Soc Clin Oncol 2001, 20(Part 2): Abst 2107.
36. Focan, C.N., Van Heugen, J.-C., Kreutz, F., Leroy, I., De Graeve, J., Blanchot, G., Zorza, G., Aerts. J., Pinel, M.-C., Puozzo, C. Vinflunine metabolism and disposition in cancer patients. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 495.
37. Delord, J.P., Stupp, R., Pinel, M.C., Nguyen, L., Vermerken, J.B. Phase I study of vinflunine given as a 10 minute intravenous (IV) infusion on a weekly schedule in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 441.
38. Vermorken, J.B., Stupp, R., Nguyen, L., Pinel, M.-C., Delord, J.-P. Phase I study of IV vinflunine given on a weekly schedule in previously untreated patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 887.
39. Bui, B., Theodore, C., Culine, S., De Santis, M., Demkow, T., Lorenz, J., Rolland, F., Fabry, F., Puget, J.C., James, N. Preliminary results of a phase II study testing intravenous (iv) vinflunine (VFL) as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder. Proc Am Soc Clin Oncol 2003, 22: Abst 1571.
40. Campone, M., Vorobiof, D., Cotes-Runes, H., Verrill, M., Khoo, K.S., Slabber, C.R, Caroff, I., Pouget, J.C., Pumoleau, P. Preliminary results of a phase II study of intravenous vinflunine as second line therapy in patients with metastatic breast cancer after anthracycline-taxane based regimen failure. 26th Annu San Antonio Breast Cancer Symp (Dec 3-6, San Antonio) 2003, Abst 355.
41. Krzakowski, M., Ramlau, R., Pinel, M., Zorza, G., Colin, C., Souquet, P. Phase I/II and pharmacokinetic study of vinflunine (VFL) in combination with cisplatin (CDDP) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients: Preliminary results. Eur J Cancer - Suppl 2003, 1(Suppl. 5): Abst 803.
42. Javlor enters two new phase III trials in NSCLC and bladder cancer. DailyDrugNews.com (Daily Essentials) September 15, 2003.
43. Bristol-Myers Squibb receives North American and Asian license for Javlor. DailyDrugNews.com (Daily Essentials) April 22, 2004.